Therapy Detail

Therapy Name Docetaxel
Therapy Description

Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Docetaxel Taxotere Docetaxel anhydrous|Docefrez Antimicrotubule Agent 11 Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FBXW7 inact mut Advanced Solid Tumor resistant Docetaxel Preclinical Actionable In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). 23274910
Clinical Trial Phase Therapies Title Recruitment Status
NCT02366494 Phase I Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel Micro RNAs to Predict Response to Androgen Deprivation Therapy Recruiting
NCT02231164 Phase III Docetaxel Nintedanib LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research Terminated
NCT03056599 Gemcitabine Interferon alfa-2b Doxorubicin Pembrolizumab Eribulin interferon gamma Ipilimumab Trabectedin Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Recruiting
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed GSK3052230 Paclitaxel + Carboplatin Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed
NCT02154490 Phase II Docetaxel Palbociclib Durvalumab AZD4547 Taselisib Erlotinib AMG102 Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer Recruiting
NCT02605915 Phase I Atezolizumab + Trastuzumab Docetaxel Carboplatin Pertuzumab Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer Active, not recruiting
NCT01630733 Phase III Docetaxel Custirsen + Docetaxel A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Unknown status
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated
NCT02283320 Phase II Docetaxel A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed
NCT03137771 Phase II Docetaxel Pemetrexed Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Recruiting
NCT01362374 Phase I Enzalutamide Paclitaxel Docetaxel Ipatasertib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors Active, not recruiting
NCT02494713 Phase II Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer Terminated
NCT01879085 Phase Ib/II Gemcitabine Docetaxel Pegfilgrastim Vorinostat Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Recruiting
NCT02574078 Phase I nab-paclitaxel Crizotinib Bevacizumab + Pemetrexed Paclitaxel Docetaxel Nivolumab Pemetrexed Gemcitabine Erlotinib Carboplatin A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370) Active, not recruiting
NCT02105636 Phase III Methotrexate Cetuximab Docetaxel Nivolumab Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Active, not recruiting
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Not yet recruiting
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Recruiting
NCT01641939 Phase III Docetaxel Paclitaxel trastuzumab emtansine A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer Terminated
NCT02257619 Phase II Docetaxel Itacitinib Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Terminated
NCT02117024 Phase II HS-110 + Cyclophosphamide Pemetrexed Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Active, not recruiting
NCT02401542 Phase II B-701 Docetaxel A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma Recruiting
NCT01779050 Phase II Trastuzumab Docetaxel Epirubicin + Cyclophosphamide Paclitaxel Fluorouracil + Epirubicin + Cyclophosphamide Docetaxel + Carboplatin Docetaxel + Cyclophosphamide Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Active, not recruiting
NCT02450539 Phase II Abemaciclib Docetaxel A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Active, not recruiting
NCT02008227 Phase III Docetaxel Atezolizumab A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK Active, not recruiting
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated
NCT01750281 Phase II Docetaxel Selumetinib + Docetaxel Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Active, not recruiting
NCT02057107 Phase II Cetuximab Docetaxel Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) Recruiting
NCT01708993 Phase II Docetaxel Pemetrexed Reolysin + Pemetrexed Reolysin + Docetaxel Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed
NCT02504489 Phase III Docetaxel Docetaxel + Plinabulin Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion Recruiting
NCT02182622 Phase I Docetaxel Sonidegib LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Unknown status
NCT02426125 Phase III Ramucirumab Docetaxel A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting
NCT01792050 Phase II Docetaxel indoximod Paclitaxel Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Unknown status
NCT03430843 Phase III Docetaxel Paclitaxel BGB-A317 Irinotecan A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting
NCT02302807 Phase III Paclitaxel Vinorelbine Atezolizumab Docetaxel A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT01780545 Phase II OGX-427 Docetaxel Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Completed
NCT03678025 Phase III Docetaxel nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting
NCT02322281 Phase III Pemetrexed Gemcitabine Paclitaxel Docetaxel CO1686 TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated
NCT03647488 Capmatinib Docetaxel Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Recruiting
NCT02395172 Phase III Avelumab Docetaxel Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Active, not recruiting
NCT01646125 Docetaxel Luminespib Pemetrexed An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated
NCT01783587 Phase I Afatinib Docetaxel Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer Active, not recruiting
NCT02551055 Phase I Docetaxel Paclitaxel Alisertib TAK-659 MLN1117 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated
NCT02599324 Phase Ib/II Docetaxel Ibrutinib Everolimus Paclitaxel Cetuximab A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting
NCT01064479 Phase II Erlotinib Carboplatin Docetaxel Cisplatin Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck Active, not recruiting
NCT02536495 Phase Ib/II Docetaxel Selinexor Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Withdrawn
NCT01633541 Phase II AT-101 Carboplatin Cisplatin Docetaxel Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer Active, not recruiting
NCT02122770 Phase I Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors Completed
NCT01472016 Phase I Docetaxel ABT-700 Cetuximab Erlotinib FOLFIRI Study of ABT-700 in Subjects With Advanced Solid Tumors Completed
NCT02387216 Phase II Seribantumab Pemetrexed Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Recruiting
NCT01810913 Phase II Docetaxel Cisplatin Docetaxel + Cetuximab Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting
NCT01828112 Phase III Docetaxel Pemetrexed Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT02252042 Phase III Pembrolizumab Methotrexate Cetuximab Docetaxel Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Active, not recruiting
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting
NCT01572038 Phase III Pertuzumab + Trastuzumab nab-paclitaxel Docetaxel Paclitaxel A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) Active, not recruiting
NCT02229149 Phase II Paclitaxel Docetaxel Pertuzumab + Trastuzumab nab-paclitaxel Vinorelbine Trastuzumab Capecitabine Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer Active, not recruiting
NCT01927744 Phase II Erlotinib + Docetaxel Cisplatin Docetaxel Carboplatin Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection Active, not recruiting
NCT02508246 Phase I Adavosertib Docetaxel Cisplatin AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifine Crizotinib Dactinomycin Temsirolimus Vorinostat romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Recruiting
NCT01911325 Phase Ib/II Buparlisib Docetaxel Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Terminated
NCT03041181 Phase II Docetaxel + Nivolumab Docetaxel Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab Recruiting